A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours - Schoffski, P; Awada, A; Dumez, H; Gil, T; Bartholomeus, S; Wolter, P; Taton, M; Fritsch, H; Glomb, P; Munzert, G (Eur J Cancer, 2012)